These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Levosimendan as rescue therapy in severe cardiogenic shock after ST-elevation myocardial infarction.
    Author: Greif M, Zwermann L, Reithmann C, Weis M.
    Journal: Acute Card Care; 2008; 10(3):185-90. PubMed ID: 18972629.
    Abstract:
    Data on the use of levosimendan in patients with myocardial infarction related cardiogenic shock already under combined catecholamine treatment and intra-aortic balloon counterpulsation (IABP) are scarce. Seven consecutive patients with refractory cardiogenic shock after ST-elevation myocardial infarction, multi-organ dysfunction syndrome and under maximal intensive care (combined catecholamine treatment, IABP) were treated with levosimendan (bolus 12 microg/kg i.v., thereafter 0.1 microg/kg over 24 h). Hemodynamic effects were registered invasively and monitored over 72h post infusion. Therapy with levosimendan significantly reduced required epinephrine dose after 48h (P=0.02 versus baseline). Norepinephrine dose had to be increased during the first 12 h of levosimendan (+25%; P=ns), but was significantly reduced at 72 h compared to baseline (median 0.14 versus 0.06 microg/kg/min after 72 h; P<0.05). Cardiac power output increased (baseline 0.6 versus 1.1 > or = 48 h after infusion; P<0.01) and systemic vascular resistance decreased (median 1294 dyn*s*cm-5 at baseline versus 858 dyn*s*cm-5 at 24 h; P<0.05) after levosimendan infusion. IABP therapy could be weaned in all patients during 5 days after infusion and all patients survived the cardiogenic shock (ICU mortality 29%). Levosimendan as an adjunctive, rescue therapy in patients with severe cardiogenic shock may be safe with beneficial effects on hemodynamics over 72 h.
    [Abstract] [Full Text] [Related] [New Search]